<DOC>
	<DOCNO>NCT00853892</DOCNO>
	<brief_summary>The objective open-label , randomize , two-period , crossover study evaluate oral bioavailability Mallinckrodt controlled-release test tablet formulation oxycodone 40 mg compare equivalent oral dose commercially available controlled-release tablet oxycodone ( OxyContin® 40 mg , Purdue Pharma L.P. ) test group healthy subject fast condition .</brief_summary>
	<brief_title>Fasting Study Controlled-Release Oxycodone Hydrochloride 40 mg Tablets OxyContin® 40 mg Tablets</brief_title>
	<detailed_description />
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female , 18 year age old . 2 . Female subject must postmenopausal least one year , surgically sterile , practice adequate nonhormonal contraception least 3 month prior duration study participation . All female subject undergo pregnancy test screen checkin clinical study site every dosing period . The result test must negative continued participation . 3 . Weight must within 15 % ideal weight height frame , adopt Metropolitan Life Insurance Co. , 1999 . 4 . Qualifying subject must good health physical condition determine screen medical history obtain within 30 day prior study start . Subjects present history significant past illness expect affect investigation . 5 . The normal status subject confirm follow procedure : 1 . Laboratory test ( serum chemistry , hematology , urinalysis ) . A subject laboratory value within clinical laboratory 's reference range qualify , unless specifically accept ( comment ) investigator . 2 . Human immunodeficiency virus ( HIV ) , drug abuse , alcohol , hepatitis B C test perform screen . Results test must negative nonreactive subject qualify study . At checkin study site , urine drug screen perform must negative continued participation . 3 . Electrocardiogram : A 12lead electrocardiogram ( ECG ) obtain subject screen . Appropriately trained experience medical personnel must interpret ECG . A subject ECG within normal range qualify , unless specifically accept ( comment ) investigator . 6 . Subjects must able provide write consent agree abide study requirement . 1 . History chronic alcohol , drug , narcotic abuse . 2 . Chronic use tranquilizer , sedative , aspirin , antibiotic , medication . 3 . History presence major organ dysfunction . 4 . History malignancy , stroke , diabetes ; cardiac , renal , liver , pulmonary , severe gastrointestinal disease ; serious illness . 5 . History anxiety , tension , severe agitation , psychosis , mental depression . 6 . Family history diagnosis epilepsy seizure disorder . 7 . History acute abdominal pelvic condition . 8 . History condition might contraindicate require caution use administration oxycodone , include renal impairment , hepatobiliary pancreatic disease , GI obstruction , cardiac disease , obstructive pulmonary disease , acute severe bronchial asthma , hypercarbia , elevate intracranial pressure , deplete blood volume , paralytic ileus , allergy oxycodone , history hypersensitivity opiate agonist 9 . Administration investigational drug 30 day prior enrollment study . 10 . Subjects smoke use nicotinecontaining product within 6 month prior study entry . 11 . Subjects donate blood within 30 day prior study entry , include withdrawn conduct clinical study . 12 . Subjects present acute illness . 13 . Subjects take prescription drug within 14 day overthecounter medication ( include herbal preparation ) within 7 day prior dose except standard daily dose multivitamin . 14 . Subjects positive Narcan® challenge .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>